After Actavis: FTC Update
Paul Hastings partner and cofounder of the life sciences patent litigation practice Bruce Wexler is a featured panelist to discuss the U.S. Supreme Court's decision in FTC v. Actavis during IPO's IP Chat Channel webinar on January 9th.
The decision in Actavis last June removed a shield that had protected the pharmaceutical industry under the “scope of the patent," under which settlement payments to generic companies in patent litigation were allowed. The Court did not go so far as to find reverse payments presumptively illegal, but rather said a settlement’s possible pro-competitive benefits must be weighed against its potential anti-competitive effects. That leaves the parties designing a settlement, in the first instance, and then lower courts and the FTC, with the job of determining whether the terms of each deal constitute a likely antitrust violation.
Join the panel as they discuss FTC v. Actavis and relevant developments since that decision.
For additional information and to register, visit the IPO site: